Suppr超能文献

加拿大对 SARS-CoV-2 血清监测的方法:常规监测和未来大流行的经验教训。

Canada's approach to SARS-CoV-2 sero-surveillance: Lessons learned for routine surveillance and future pandemics.

机构信息

Epidemiology & Surveillance, Canadian Blood Services, Ottawa, ON, Canada.

School of Epidemiology & Public Health, University of Ottawa, Ottawa, ON, Canada.

出版信息

Can J Public Health. 2024 Aug;115(4):558-566. doi: 10.17269/s41997-024-00901-w. Epub 2024 Jul 9.

Abstract

SETTING

In Canada's federated healthcare system, 13 provincial and territorial jurisdictions have independent responsibility to collect data to inform health policies. During the COVID-19 pandemic (2020-2023), national and regional sero-surveys mostly drew upon existing infrastructure to quickly test specimens and collect data but required cross-jurisdiction coordination and communication.

INTERVENTION

There were 4 national and 7 regional general population SARS-CoV-2 sero-surveys. Survey methodologies varied by participant selection approaches, assay choices, and reporting structures. We analyzed Canadian pandemic sero-surveillance initiatives to identify key learnings to inform future pandemic planning.

OUTCOMES

Over a million samples were tested for SARS-CoV-2 antibodies from 2020 to 2023 but siloed in 11 distinct datasets. Most national sero-surveys had insufficient sample size to estimate regional prevalence; differences in methodology hampered cross-regional comparisons of regional sero-surveys. Only four sero-surveys included questionnaires. Sero-surveys were not directly comparable due to different assays, sampling methodologies, and time-frames. Linkage to health records occurred in three provinces only. Dried blood spots permitted sample collection in remote populations and during stay-at-home orders.

IMPLICATIONS

To provide timely, high-quality information for public health decision-making, routine sero-surveillance systems must be adaptable, flexible, and scalable. National capability planning should include consortiums for assay design and validation, defined mechanisms to improve test capacity, base documents for data linkage and material transfer across jurisdictions, and mechanisms for real-time communication of data. Lessons learned will inform incorporation of a robust sero-survey program into routine surveillance with strategic sampling and capacity to adapt and scale rapidly as a part of a comprehensive national pandemic response plan.

摘要

背景

在加拿大的联邦医疗保健系统中,13 个省级和地区行政单位负责独立收集数据以制定卫生政策。在 COVID-19 大流行期间(2020-2023 年),全国和地区血清学调查主要利用现有基础设施快速检测样本和收集数据,但需要跨辖区协调和沟通。

干预措施

进行了 4 项全国性和 7 项地区性一般人群 SARS-CoV-2 血清学调查。调查方法因参与者选择方法、检测选择和报告结构而异。我们分析了加拿大大流行血清学监测计划,以确定关键经验教训,为未来的大流行规划提供信息。

结果

2020 年至 2023 年,对超过 100 万个样本进行了 SARS-CoV-2 抗体检测,但这些数据分别保存在 11 个独立的数据集中。大多数全国性血清学调查的样本量不足以估计区域性流行率;方法上的差异阻碍了地区性血清学调查的跨地区比较。只有四项血清学调查包括问卷调查。由于检测方法、采样方法和时间框架不同,血清学调查无法直接比较。只有三个省进行了与健康记录的链接。仅在三个省进行了与健康记录的链接。干血斑允许在偏远地区和居家令期间采集样本。

影响

为了为公共卫生决策提供及时、高质量的信息,常规血清学监测系统必须具有适应性、灵活性和可扩展性。国家能力规划应包括检测设计和验证联盟、提高检测能力的明确机制、用于跨辖区数据链接和材料转移的基本文件,以及实时数据通信机制。经验教训将为将一个强大的血清学调查计划纳入常规监测提供信息,包括有策略地进行抽样,以及作为全面国家大流行应对计划的一部分,快速适应和扩大规模的能力。

相似文献

1
Canada's approach to SARS-CoV-2 sero-surveillance: Lessons learned for routine surveillance and future pandemics.
Can J Public Health. 2024 Aug;115(4):558-566. doi: 10.17269/s41997-024-00901-w. Epub 2024 Jul 9.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
4
Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.
PLoS One. 2025 May 6;20(5):e0313791. doi: 10.1371/journal.pone.0313791. eCollection 2025.
5
Measures implemented in the school setting to contain the COVID-19 pandemic.
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
6
Laboratory-based molecular test alternatives to RT-PCR for the diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2024 Oct 14;10(10):CD015618. doi: 10.1002/14651858.CD015618.
7
Physical interventions to interrupt or reduce the spread of respiratory viruses.
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
8
Unintended consequences of measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review.
Cochrane Database Syst Rev. 2024 Dec 12;12(12):CD015397. doi: 10.1002/14651858.CD015397.pub2.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.

引用本文的文献

1
Influenza and COVID-19 vaccination in Canadian blood donors: A comparison across pre- and post-pandemic periods.
Vox Sang. 2025 May;120(5):464-472. doi: 10.1111/vox.70006. Epub 2025 Feb 27.

本文引用的文献

1
Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022.
BMC Public Health. 2023 Dec 5;23(1):2420. doi: 10.1186/s12889-023-17239-6.
2
The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023.
CMAJ. 2023 Aug 14;195(31):E1030-E1037. doi: 10.1503/cmaj.230249.
4
Development of hybrid immunity during a period of high incidence of Omicron infections.
Int J Epidemiol. 2023 Dec 25;52(6):1696-1707. doi: 10.1093/ije/dyad098.
5
6
Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence study.
CMAJ Open. 2023 Apr 4;11(2):E305-E313. doi: 10.9778/cmajo.20220045. Print 2023 Mar-Apr.
9
SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron.
Viruses. 2022 Oct 25;14(11):2336. doi: 10.3390/v14112336.
10
Evaluation of the performance of multiple immunoassay diagnostic platforms on the National Microbiology Laboratory SARS-CoV-2 National Serology Panel.
J Assoc Med Microbiol Infect Dis Can. 2022 Sep 27;7(3):186-195. doi: 10.3138/jammi-2021-0026. eCollection 2022 Sep.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验